ABSTRACT: Amantadine inhibits the M2 proton channel of influenza A virus, yet most of the currently circulating strains of the virus carry mutations in the M2 protein that render the virus amantadine-resistant. While most of the research on novel amantadine analogues has revolved around the synthesis of novel adamantane derivatives, we have recently found that other polycyclic scaffolds effectively block the M2 proton channel, including amantadine-resistant mutant channels. In this work, we have synthesized and characterized a series of pyrrolidine derivatives designed as analogues of amantadine. Inhibition of the wild-type M2 channel and the A/M2-S31N, A/M2-V27A, and A/M2-L26F mutant forms of the channel were measured in Xenopus oocytes using two-electrode voltage clamp assays. Most of the novel compounds inhibited the wildtype ion channel in the low micromolar range. Of note, two of the compounds inhibited the amantadine-resistant A/M2-V27A and A/M2-L26F mutant ion channels with submicromolar and low micromolar IC 50 , respectively. None of the compounds was found to inhibit the S31N mutant ion channel.
■ INTRODUCTION
Amantadine (Amt) and rimantadine (Rmt), two polycyclic aminoadamantane derivatives, have been in clinical use as antiinfluenza virus agents for decades. However, the efficacy of these two drugs dropped sharply in recent years due to the global distribution of mutant viruses carrying Amt resistance mutations, prompting the Centers for Disease Control to recommend discontinuing the use of amantadine-based drugs.
1,2 Therefore, there is an urgent need to develop novel antiviral drugs that are active against drug-resistant influenza viruses.
The mechanism of action of Amt and Rmt is based on the inhibition of the M2 proton channel of the influenza A virus. The M2 protein is a 97 residues long integral membrane protein with a transmembrane (TM) domain of 19 residues, a small ectodomain of 23 residues, and a 54 residues long cytoplasmic tail. 3−5 Detailed mutational studies indicated that several point mutations of pore-lining residues of the A/M2 TM domain result in Amt-resistance. 6 However, only a few of these mutations (i.e., L26F, V27A, and S31N) have been observed in transmissible viruses, with the S31N mutation being the most frequently occurring Amt-resistance mutation. 7 In 2011, Wang et al. reported that spiro compound 1 is able of inhibiting the L26F and V27A M2 mutants with good efficacy in electrophysiological and plaque reduction assays. 8−10 More recently, our group has reported the first non-adamantane inhibitor of the V27A mutant, the polycyclic pyrrolidine 2 (Chart 1).
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A common problem of 1 and 2 is that their syntheses involves several steps (e.g., up to 11 steps for 2), 11 which means that the synthesis of novel analogues of these two compounds would be challenging. In the present study, we report novel scaffolds designed to inhibit the A/M2 channel. We have found that the wild-type (wt) channel can be inhibited by several easyaccessible pyrrolidine derivatives. Furthermore, we have identified two compounds, 18 and 19, that are capable of inhibiting the M2-V27A mutant ion channel with submicromolar IC 50 values. In addition, both compounds are able to inhibit the M2 wt channel with an IC 50 value similar to that of Amt, and both are also low micromolar inhibitors of the M2-L26F mutant channel.
■ CHEMISTRY
During the past years, our group has synthesized several polycyclic Amt analogues containing different scaffolds, including ring-contracted, ring-rearranged, and 2,2-dialkyl derivatives of Amt. 12−15 Several of them displayed similar IC 50 values for wt A/M2 as Amt but, unfortunately, were inactive against the Amt-resistant S31N or V27A mutant forms of A/M2. 13 More recently, we have reported on the synthesis of polycyclic pyrrolidines and on their inhibitory effect on the A/ M2 proton channel activity by using the conductance assay in M2-expressing oocytes. Again, several of these novel compounds displayed similar IC 50 values for wt A/M2 as Amt, and, interestingly, we found three guanidine derivatives that displayed low micromolar to submicromolar IC 50 values against the V27A mutant channel. 11 On the basis of our previous insights that polycyclic scaffolds other than adamantane effectively inhibit the M2 proton channel and that the synthesis of guanidine 2 and related compounds involved a very long synthetic sequence, we have searched for novel synthetic strategies able to yield polycyclic amines that are structurally diverse and easily available by short synthetic sequences.
The reduction of known imide 3, easily accessible in multigram quantities by the reaction of commercially available cycloheptatriene with maleimide, 16 furnished amine 4 in 79% yield. The catalytic hydrogenation of 4 led to fully saturated compound 6 in 95% yield. Both pyrrolidines were transformed into their corresponding guanidines, 5 and 7, by reaction with 1H-pyrazole-1-carboxamidine. Taking into account that recent experimental and computational studies have shown that the M2-V27A mutant channel has a larger cavity than the wt M2 channel, 9,17−19 we also synthesized larger compounds derived from 4 and 6. Thus, reductive alkylation of amine 4 with 1-Boc-4-piperidone followed by deprotection led to piperidine 8 in 75% overall yield. The catalytic hydrogenation of 8 furnished piperidine 9 in 85% yield (Scheme 1). Similarly, starting from known imide 10, easily available from cyclooctatetraene and maleimide, 16 amines 11 and 12 and their guanidine derivatives 13 and 14, were synthesized in good yields (Scheme 1).
To increase the chemical diversity of the compounds, while preserving the synthetic easiness, two more compact pyrrolidine derivatives, 18 and 19, were designed (Scheme 2). For the synthesis of these aesthetically appealing compounds that include one four-membered ring, three fivemembered rings, and two six-membered rings, we started from known diacid 15, easily available from acetylene dicarboxylic acid and 2,3-dimethylbutadiene. 20, 21 The reaction of 15 with urea at 180°C for 30 min yielded imide 16 in 75% yield. Photolysis of imide 16 at room temperature in acetone with a 125 W Hg lamp for 2 days gave a mixture of the starting imide and the tetracyclic imide 17. Column chromatography of this mixture through silica gel afforded pure 17 in 36% yield (based on recovered starting material, brsm). The imide was subsequently reduced using sodium bis(2-methoxyethoxy)-aluminum hydride to give the secondary amine 18 in 71% yield. Finally, reaction of 18 with 1H-pyrazole-1-carboxamidine monohydrochloride in acetonitrile led to guanidine 19 in 66% yield (Scheme 2).
Previously, we have seen that, in related polycyclic compounds, on going from secondary to tertiary amines, the inhibitory effect on either wt or V27A mutant M2 channels diminished. 6, 11, 15 For this reason, in this work we have not synthesized alkylated derivatives of the novel secondary amines herein reported.
All the new compounds were fully characterized as hydrochlorides through their spectroscopic data and elemental analyses.
Pharmacological Activity and Structure−Activity Relationships. Inhibition of wt and Amt-Resistant A/M2 Ion Channels. The inhibitory activity of the compounds was tested on A/M2 channels expressed in Xenopus oocytes using the two-electrode voltage clamp (TEV) technique. All inhibitors were initially tested at 100 μM; those that inhibited the wt A/M2 channel activity by more than 80% were chosen for measurement of their IC 50 value in an isochronic (2 min) inhibition assay. The results are given in Table 1 .
Amt inhibited wt A/M2 channel with an IC 50 of 16.0 μM while being inactive against the V27A mutant channel. Unfortunately, piperidine derivatives 8 and 9 did not display any activity. Tetracyclo amines 4, 6, 11, and 12 and their corresponding guanidines 5, 7, 13, and 14 were potent lowmicromolar inhibitors of the wt channel. Regarding the activity against the V27A M2 mutant channel, three trends were found, i.e., guanidine performed better than its corresponding amine (e.g., 7 vs 6 or 13 vs 11), the fully saturated compounds were more potent than their corresponding unsaturated analogues (e.g., 7 vs 5 or 14 vs 13), and the cyclobutane/cyclobutene analogues were more potent than the cyclopropane derivatives (e.g., 12 vs 6 or 14 vs 7). Altogether, guanidine 14 emerged as the more promising compound, being more potent than Amt against the wt M2 channel and endowed with fair activity against the V27A mutant channel. None of the compounds was found to inhibit the S31N mutant ion channel. Finally, amine 18 and guanidine 19 also proved to be active against the wt channel, with similar IC 50 values as Amt (18.5 and 10.7 μM, respectively) while being endowed with submicromolar IC 50 against the V27A mutant (0.7 and 0.5 μM, respectively). Moreover, both compounds were low micromolar inhibitors of the L26F mutant (8.6 and 7.5 μM, respectively). Molecular Modeling. To gain insight into the inhibitory data of the more compact pyrrolidine derivatives, the interaction of 18 with the wt M2 channel and its V27A variant was examined by means of molecular dynamics (MD) simulations and compared with the trends found for the binding of Amt.
The analysis of the three replicas run for 18 bound to the wt channel shows a consistent binding mode, where the center-ofmass (COM) of the inhibitor is located close to the plane formed by the Cα atoms of Ser31, the amine nitrogen is pointing toward the plane formed by the His37 residues (average distance of 6.1 Å), and the tilt angle (i.e., the deviation of the amine nitrogen from the pore axis) is 16.1°, which partly reflects the twisted geometry of the pyrrolidine ring (Figure 1 ; see also Supporting Information Figure S1 ). This orientation (denoted down hereafter) is also found for Amt bound to the wt channel (Supporting Information Figure S2 ). In two replicas of the V27A−18 complex, the inhibitor adopts the down orientation, but in the third replica it turns over at the beginning of the trajectory and the inhibitor adopts the opposite (up) orientation (the distance of the amine nitrogen to the His37 plane and the tilt angle are, on average, 14.9 Å and 145.3°; Figure 1 and Supporting Information Figure S3 ). Remarkably, Amt was found in the up orientation in the three replicas run for the V27A channel (Supporting Information Figure S4 ), and even in one case Amt was released to the solvent after few nanoseconds.
To explore the molecular basis of the exchange between down and up orientations found in the V27A channel, additional MD simulations were run for the apo forms of both wt and V27A channels. The root-mean-square deviation (RMSD) of the protein backbone for the transmembrane helices between the wt channel and its V27A variant amounts to 1.4 Å, which compare with the typical range of RMSD values obtained for the ligand-bound forms of the two channels (between 1.2 and 1.7 Å; Supporting Information Table S1 ). This suggests that the gross structural features of the channel are not drastically altered by the Val27 → Ala mutation, in agreement with previous studies. 9, 18 Nevertheless, inspection of the interhelical cross-diagonals distances (measured from either the Cα or the Cβ atoms) for distinct tetrads of residues shows that the mutation widens the pore at the Ala27 plane, an effect associated with the narrowing of the pore at the His37 plane (Table 2 ). This structural rearrangement likely contributes to the displacement of the amine nitrogen of compound 18 in the V27A channel, which is pushed away from the His37 plane by 1.6 Å (from 6.1 Å in the wt channel to 7.7 Å in the V27A variant for the inhibitor in the down orientation) and might facilitate the exchange between down and up arrangements of the inhibitor. Compared to compound 18, the lower, more compact size of Amt should likely enhance the exchange rate between the two ligand orientations, eventually leading to an easier release from the pore that could account for the reduction in inhibitory potency against the V27A channel ( Table 1 ). The lack of inhibitory potency of compound 18 against the S31N variant can be realized from the comparison of the inhibitor bound to the wt M2 channel and the solid-state NMR-derived structural data available for the complex of the S31N channel bound to the 5-thienyl isoxazole derivative containing a 1-(1-adamantylamino)-methylene group in position 3 (PDB entry 2LY0). 22 It was noted that the structure of the S31N variant closely resembled previous structures of the wt M2 channel, showing most similarity to the Amt-bound channel structure solved by solid-state NMR. 23 Similar structural resemblance is also found upon comparison with the snapshots sampled for the wt channel bound to compound 18 (see Supporting Information Figure S6 ), which rules out the existence of drastic structural alterations in the arrangement of the transmembrane helices triggered upon binding of the two compounds. Both NMR and MD simulations revealed that binding of the isoxazole derivative involved water-mediated contacts between the protonated amine group with two Asn31 side chains as well as by a direct interaction between the amide unit of a third Asn31 and the charged amine group. This network of interactions was facilitated by the fact that the adamantylamino group was oriented with the amine facing away the His37 plane. However, the position of the protonated amine unit in the isoxazole derivative is replaced by the hydrophobic cage of compound 18 (see Supporting Information Figure S6 ), which would thus be unable of forming a similar pattern of stabilizing interactions. On the other hand, adoption of the reverse arrangement of compound 18 (i.e., adopting an amine-up orientation) should not only alter the contacts with Asn31 due to the distinct orientation of the amine group but would also trigger unfavorable clashes between the terminal methyl groups with the tetrad of Gly37 residues.
Antiviral Activity. The anti-influenza virus activity of the compounds was first assessed in a relatively stringent three-day cytopathic effect (CPE) reduction assay in MDCK cells (Table  3 ). All the guanidines showed to be inactive, probably reflecting a permeability problem or, particularly for 13, 14, and 19, as a consequence of their cytotoxicity. Compounds 4 and 6 displayed favorable activity (i.e., antiviral EC 50 values in the range of 3−8 μM) against the A/HK/7/87 virus strain, which possesses a wt M2 channel. Three other compounds, i.e., 8, 11, and 18, showed strong activity against the A/PR/8/34 strain, an A/H1N1 virus with two mutations (S31N and V27T) in the M2 protein. We previously found that A/PR/8/34 appears particularly sensitive to a slight increase in endosomal pH as induced by some polycyclic amine compounds. 15 This effect may explain, at least in part, the antiviral activity of these compounds, although they were devoid of activity against the S31N M2 mutant channel. A similar behavior has very recently been observed by Kolocouris et al. in a set of novel aminoadamantanes. 24 We subsequently performed a 24 h virus yield assay and a plaque reduction assay, both using the WT-M2 A/HK/7/87 virus. These experiments confirmed the activity of 4 and 6 (Table 3 and Figure 2 ), which, in terms of cell culture activity, emerged as the two most promising molecules among the synthesized series. Compounds 12 and 14 were shown to reduce virus yield, with EC 99 values of <0.08 μM (12) and 4.6 μM (14). These compounds caused a clear (12) or modest (14) reduction in plaque size or number at a compound concentration of 0.5 μM (Figure 2 ). However, because both were visibly toxic at 2−8 μM, their selectivity index (i.e., ratio of cytotoxic to antivirally effective concentration) appears limited. Finally, 11, 13, and 18 caused visible inhibition of plaque formation (Figure 2 ) at 0.5−2 μM, but the activity of these three compounds was not confirmed in the CPE or virus yield assay ( Table 3) . As expected, neither the novel compounds nor the reference agents Amt and Rmt were active against influenza B virus (data not shown).
■ CONCLUSIONS
The present work shows the feasibility of designing easily accessible compounds able to successfully inhibit the wt and the V27A and L26F variants of the A/M2 channels of influenza A virus. In fact, some of the newly designed compounds inhibit the three channels similarly or even more effectively than Amt inhibits the wt proton channel. In particular, amine 18 and guanidine 19 emerged as promising compounds, being low micromolar inhibitors against the wt channel and the L26F mutant, while being endowed with submicromolar IC 50 against the V27A variant. Furthermore, compound 18 showed strong activity against the A/PR/8/34 strain, an A/H1N1 virus with two mutations (S31N and V27T) 
■ EXPERIMENTAL SECTION
Plasmid, mRNA Synthesis, and Microinjection of Oocytes. The cDNA encoding the influenza A/Udorn/72 (A/M2) was inserted into pGEM3 vector for the expression on oocyte plasma membrane. A/M2 S31N and A/M2 V27A mutants were generated by QuikChange site-directed mutagenesis kit (Agilent Technologies). The synthesis of mRNA and microinjection of oocytes have been described previously. 26 Two-Electrode Voltage Clamp Analysis. Macroscopic membrane current was recorded 48−72 h after injection as described previously. 8 The tested compounds were applied at pH 5.5 at various concentrations when the inward current reaches maximum. The compounds were applied for 2 min, and residual membrane current was compared with the membrane current before the application of compounds. Membrane currents were analyzed with pCLAMP 10.0 software package (Axon Instruments, Sunnyvale, CA).
Antiviral Assays. To determine the anti-influenza virus activity in Madin−Darby canine kidney (MDCK) cells, CPE reduction and virus yield assays were performed as described. 25, 27 Briefly, MDCK cells grown in 96-well plates were infected with influenza virus (strains A/ PR/8/34 (A/H1N1); A/HK/7/87 (A/H3N2) or B/HK/5/72), and at the same time the test compounds were added in serial dilutions. After 72 h incubation at 35°C, microscopy was performed to score the compounds' inhibitory effect on the viral cytopathic effect (CPE) or cytotoxicity. These data were verified by measuring the cell viability with the formazan-based MTS assay. In separate experiments, supernatants were harvested from the infected and compound-treated cells at 24 h post infection, and virus yield in these samples was determined by qRT-PCR. To perform plaque reduction assays, influenza virus A/HK/7/87 was incubated (1 h at 4°C) ]dodec-11-ene Hydrochloride, 4·HCl. A solution of imide 3 (8.00 g, 42.3 mmol) in dry and degassed toluene (280 mL) was cooled down to 5°C with an ice bath. Sodium bis(2-methoxyethoxy) aluminum hydride (64.5 mL, 65% solution in toluene, 211.4 mmol) was added dropwise, and the resulting solution was heated to reflux and stirred for 2 days. The solution was allowed to cool down to room temperature, and 30% aqueous KOH (300 mL) was added dropwise. The organic phase was separated and the aqueous layer was extracted with dichloromethane (3 × 250 mL). The combined organic extracts were dried over Na 2 SO 4 , filtered, and concentrated under vacuo to give a red oil. This oil was dissolved in EtOAc and treated with an excess of a 1.2 N ethereal solution of HCl and was allow to stand at 0°C for 24 h. The suspension was filtered to get 4·HCl as a white solid (6.54 g, 79% To a solution of 4·HCl (1.15 g, 5. 8 mmol) in water (30 mL) was added a 10 N aqueous solution of NaOH. It was then extracted with EtOAc (3 × 50 mL), and the organic phase was dried over Na 2 SO 4 , filtered, and concentrated under vacuo (yellowish oil, 945 mg, quantitative yield). This oil was dissolved in MeOH (20 mL), and sodium cyanoborohydride (1.06 g, 16.9 mmol), 1-Boc-4-piperidone (1.39 g, 7.0 mmol), and glacial acetic acid (0.67 mL) were added to the solution. The solution was stirred at room temperature for 8 h, and a second portion of sodium cyanoborohydride (1.06 g, 16.9 mmol) and 1-Boc-4-piperidone (1.39 g, 7.0 mmol) were added. The yellow solution was further stirred at room temeprature overnight. It was concentrated under vacuo, and the yellow oil was redissolved in water (50 mL) and extracted with EtOAc (3 × 50 mL). The organic phase was dried over Na 2 SO 4 , filtered, and concentrated under vacuo (clear sticky solid, 3.90 g). Column chromatography of the solid (silica gel, EtOAc) gave the pure carbamate as an off-white solid (1.52 g, 76% (35 mL) , Pd on charcoal (40 mg, ca. 10% Pd) was added and the resulting suspension was hydrogenated at room temperature and at 150 psi of H 2 overnight. The black suspension was filtered, and 9·2HCl was recovered as a white solid (170 mg, 85% ). An analytical sample was obtained by crystallization from MeOH, mp >300°C (dec.). IR (KBr) ν 3422, 2929, 2889, 2840, 2779, 2726, 2646,  2608, 2495, 2453, 2419, 2371, 1609, 1473, 1399, 1364, 1288, 1098 , 1078, 879, 841, 800, 610, 510 cm
1 H NMR (400 MHz, CD 3 OD) δ 0.59 (td, J = 7.6 Hz, J′ = 6 Hz, 1 H, 9-H a ), 1.00 (m, 1 H, 9-H 83 mmol) in water (30 mL) was basified to pH = 14 with a 10 N aqueous solution of NaOH. It was then extracted with EtOAc (3 × 50 mL), and the joined organic phase was dried over Na 2 SO 4 , filtered off, and concentrated under vacuo (yellow oil, 900 mg, 5.55 mmol, 95% yield). To a suspension of this oil in acetonitrile (35 mL), 1H-pyrazole-1-carboxamidine monohydrochloride (1.08 g, 7.40 mmol) was added. The suspension was heated to reflux for 6 h. The yellow precipitate was filtered to give 5·HCl as yellow crystals (1.13 g, 85% ). (26) .
Molecular Modeling. The binding mode of Amt and compound 18 to the wt M2 channels and its V27A variant embedded on a model bilayer of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was studied by molecular dynamics simulations. The M2 channel was modeled from the solid-state NMR structure obtained by Sharma et al. 28 (PDB entry 2L0J), and it was oriented using as template the solid state NMR structure with PDB entry 2KQT 23 as deposited in the Orientations of Proteins in Membranes (OPM) database. 29 The X-ray crystallographic structure 3LBW from the Protein Data Bank was used to model the position of water molecules inside the channel. 30 The initial position of the ligands was chosen to resemble the orientation of Amt in the 2KQT structure.
The CHARMM-GUI web server was used to build up the initial systems. 31−33 Briefly, the complex formed by the protein, the inner lumen water molecules, and the ligand was embedded on a 100 Å × 100 Å POPC bilayer patch. A 25 Å layer of TIP3P 34 water molecules was set up at both sides of the bilayer, and K + cations and Cl − anions were added to achieve an ionic strength of 150 mM. The Parm99SB force field was used for the protein, 35 the ligands were parametrized using the gaff force field 36 in conjunction with RESP (HF/6-31G(d)) charges 37 as implemented in the Antechamber module of AMBER12 software package, 38 and the POPC molecules were parametrized according to the GAFF-lipid force field. 39 Joung and Cheatham parameters were used to model the counterions. 40 Each system comprised around 97000 atoms, including the protein ligand complex, 265 POPC molecules, around 58000 waters and 108 (51 K + ; 57 Cl − ) counterions in a simulation box of 100000 Å 3 . The geometry of the system was minimized in five cycles that combined 3500 steps of steepest descent algorithm followed by 4500 of conjugate gradient. Thermalization of the system was performed in 5 steps of 1 ns, where the temperature was gradually increased from 50 K to 298 K, while the protein, ligand, and POPC molecules were restrained with a force constant of 1 kcal mol −1 Å −2 . Prior to the production runs, a set of 20 ns simulations was performed to smoothly equilibrate the systems by gradually reducing the restraints first for the POPC molecules (restraints reduced by 0.1 kcal mol −1 Å −2 at each step) and then for the protein (restraints reduced by 0.2 kcal mol −1 Å −2 at each step). At this point, three different replicas were generated for each ligand−protein complex (accounting for a total of 12 different simulation systems).
We took advantage of the GPU-accelerated PMEMD module from AMBER12 software package for the production runs, 41 which consisted of 50 ns trajectories (accounting for a global simulation time of 600 ns) using SHAKE for bonds involving hydrogen atoms, a time step of 2 fs, periodic boundary conditions using anisotropic constant pressure and temperature (298 K; Langevin thermostat with a collision frequency of 3 ps −1 ), particle mesh Ewald for long-range electrostatic interactions, and a cutoff of 10 Å for nonbonded interactions.
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